603739 Stock Overview
Engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Qingdao Vland Biotech INC. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.19 |
| 52 Week High | CN¥22.35 |
| 52 Week Low | CN¥7.70 |
| Beta | 0.44 |
| 1 Month Change | -5.11% |
| 3 Month Change | 27.56% |
| 1 Year Change | -3.86% |
| 3 Year Change | -26.93% |
| 5 Year Change | -25.03% |
| Change since IPO | 25.88% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Qingdao Vland Biotech INC.'s (SHSE:603739) 28% Share Price Surge
Nov 08
Qingdao Vland Biotech's (SHSE:603739) Anemic Earnings Might Be Worse Than You Think
Nov 04Recent updates
Why Investors Shouldn't Be Surprised By Qingdao Vland Biotech INC.'s (SHSE:603739) 28% Share Price Surge
Nov 08Qingdao Vland Biotech's (SHSE:603739) Anemic Earnings Might Be Worse Than You Think
Nov 04Some Qingdao Vland Biotech INC. (SHSE:603739) Shareholders Look For Exit As Shares Take 27% Pounding
Sep 05Qingdao Vland Biotech INC.'s (SHSE:603739) Popularity With Investors Under Threat As Stock Sinks 26%
Jun 07Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings
May 06Qingdao Vland Biotech INC. (SHSE:603739) Might Not Be As Mispriced As It Looks
Apr 16Shareholder Returns
| 603739 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -7.8% | -1.9% | -1.2% |
| 1Y | -3.9% | -16.2% | 11.8% |
Return vs Industry: 603739 exceeded the CN Biotechs industry which returned -16.2% over the past year.
Return vs Market: 603739 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 603739 volatility | |
|---|---|
| 603739 Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 603739 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603739's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1,571 | Gang Chen | www.vlandgroup.com |
Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics.
Qingdao Vland Biotech INC. Fundamentals Summary
| 603739 fundamental statistics | |
|---|---|
| Market cap | CN¥3.34b |
| Earnings (TTM) | CN¥66.23m |
| Revenue (TTM) | CN¥1.26b |
50.4x
P/E Ratio2.6x
P/S RatioIs 603739 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603739 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.26b |
| Cost of Revenue | CN¥686.71m |
| Gross Profit | CN¥578.17m |
| Other Expenses | CN¥511.94m |
| Earnings | CN¥66.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 45.71% |
| Net Profit Margin | 5.24% |
| Debt/Equity Ratio | 40.4% |
How did 603739 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield39%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 14:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Qingdao Vland Biotech INC. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiarui Lu | Guosen Securities Co., Ltd. |
| Hairong Liu | Minsheng Securities Co. |
| Xuemei Yao | Zhongtai Securities Co. Ltd. |